The Cancer Letter

Inside information on cancer research and drug development

In Brief

Max Foundation, ABC Global Alliance, American Society of Clinical Pathology, Cepheid, Novartis AG collaborate to improve advanced breast cancer outcomes in low-resource countries

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print
BYLINE
IN THIS ISSUE
DOWNLOAD PDFTABLE OF CONTENTS

The Max Foundation, the ABC Global Alliance, the American Society of Clinical Pathology, Cepheid, and Novartis AG are joining and committing resources to improve outcomes for people living with HR+/HER2- advanced breast care in low- and middle-income countries.

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Table of Contents

YOU MAY BE INTERESTED IN

In Brief

NCI funds a $3.7M effort to develop AI that predicts breast cancer risk while addressing health disparities

Researchers at Indiana University School of Medicine, Mayo Clinic, Washington University in St. Louis, the University of Pennsylvania, Columbia University, and Intel received a five-year, $3.7 million NCI grant for a multi-site study developing a privacy-preserving artificial intelligence approach—called federated learning—which aims to improve breast cancer risk prediction and reduce health inequities in cancer prevention care. 
Table of Contents

Can you spare 10 minutes to complete a survey?

Your feedback is really important—you're helping us shape our coverage priorities and services to better serve you, our readers.
COMPLETE OUR SURVEY

Login

Site license subscribers:
Log in with your IP | Register a sponsored account